{"disease":{"id":"gene-mutations","name":"gene mutations"},"drugs":{"marketed":[{"drug_id":"talazoparib-with-enzalutamide","indication_name":"Metastatic castration-resistant prostate cancer (mCRPC) with BRCA1, BRCA2, or ATM gene mutations","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Talazoparib with enzalutamide","generic_name":"talazoparib-with-enzalutamide","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP enzymes and androgen receptor","drug_class":"PARP inhibitor and androgen receptor inhibitor","quality_score":10,"revenue":"2194","mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT00628745","title":"Transthyretin Amyloidosis Outcome Survey (THAOS)","phase":"","overall_status":"COMPLETED","enrollment_count":6718,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02849977","title":"Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers","phase":"","overall_status":"COMPLETED","enrollment_count":5966,"lead_sponsor_name":"Rhythm Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03538639","title":"Vascular Disease Discovery Protocol","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT06277466","title":"Effect of Mutations in T2DM Susceptibility Genes on the Expression of Susceptibility Genes in Patients With T2DM and Controls","phase":"NA","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"The Affiliated Hospital of Xuzhou Medical University","has_results":false},{"nct_id":"NCT02202291","title":"Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon","phase":"NA","overall_status":"COMPLETED","enrollment_count":258,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT02699190","title":"LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies","phase":"","overall_status":"COMPLETED","enrollment_count":236,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":true},{"nct_id":"NCT03451877","title":"TGFB1 And LAMA1 Gene Polymorphisms in High Myopia","phase":"NA","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Ege University","has_results":false},{"nct_id":"NCT01760655","title":"Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT06701396","title":"Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Vanda Pharmaceuticals","has_results":false},{"nct_id":"NCT01904136","title":"Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":54,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT03588078","title":"Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Groupe Francophone des Myelodysplasies","has_results":false},{"nct_id":"NCT07343479","title":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03333486","title":"Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT04493164","title":"CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06313437","title":"Revumenib in Combination With 7+3 + Midostaurin in AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":22,"lead_sponsor_name":"Richard Stone, MD","has_results":false},{"nct_id":"NCT04770246","title":"TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":17,"lead_sponsor_name":"Taiho Oncology, Inc.","has_results":false},{"nct_id":"NCT02341807","title":"Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03887169","title":"Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06678685","title":"Spironolactone Improved Children With Gene Mutations Related to NCOR","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT02634827","title":"Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT06019481","title":"A Natural History Study in Pediatric Participants With Hearing Loss Due to OTOF, GJB2, or GJB2/GJB6 Mutations","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT03746912","title":"Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Daiichi Sankyo","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}